1-10 of 10
Lisa L. Smith, MS
Close
Sort by
Journal Articles

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Kerry A. Rogers, MD, Amy M. Lehman, MAS, Carolyn Cheney, BS, Virginia M. Goettl, DVM , PhD, Rose Mantel, Lisa L. Smith, MS, Minh Tran, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2016) 128 (22): 1259.
https://doi.org/10.1182/blood.V128.22.1259.1259
Published: 2016
Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Sean D. Reiff, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Virginia M. Goettl, DVM , PhD, Amy J. Johnson, PhD, Sudharsan Eathiraj, Giovanni Abbadessa, MD, Brian Schwartz, MD, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2016) 128 (22): 3232.
https://doi.org/10.1182/blood.V128.22.3232.3232
Published: 2016
Journal Articles

Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo

Fabienne McClanahan, MD PhD, Sean D. Reiff, Daphne Guinn, PhD, Minh Tran, Larry Beaver, Samantha McWorther, Rose Mantel, Lisa L. Smith, MS, Amy J. Johnson, PhD, John C. Byrd, MD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2016) 128 (22): 352.
https://doi.org/10.1182/blood.V128.22.352.352
Published: 2016
Journal Articles

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jennifer A. Woyach, MD, Daphne Guinn, PhD, Amy S. Ruppert, MAS, James S. Blachly, MD, Arletta Lozanski, MS, Nyla A. Heerema, PhD, Weiqiang Zhao, MD PhD, Joshua Coleman, MD, Daniel Jones, Lynne V. Abruzzo, MD PhD, Amber Gordon, MLS, Rose Mantel, Lisa L. Smith, MS, Samantha McWhorter, Melanie Davis, PhD, Tzyy-Jye Doong, PhD, Fan Ny, CNP, Margaret S. Lucas, PA-C, Weihong Chase, CNP, Jeffrey Jones, MD MPH, Joseph M. Flynn, DO, MPH, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Kristie Blum, MD, Michael R. Grever, MD, Gerard Lozanski, MD, John C. Byrd, MD, Amy J. Johnson, PhD
Journal: Blood
Blood (2016) 128 (22): 55.
https://doi.org/10.1182/blood.V128.22.55.55
Published: 2016
Journal Articles

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Kerry A. Rogers, MD, Dalia El-Gamal, PhD, Harrington K. Bonnie, DVM, Hing A. Zachary, BS, Goettl M. Virginia, DVM, PhD, Mantel Rose, Lisa L. Smith, MS, Lianbo Yu, PhD, Amy J. Johnson, PhD, John C. Byrd, MD, Rosa Lapalombella, PhD, Jennifer A. Woyach, MD
Journal: Blood
Blood (2015) 126 (23): 2752.
https://doi.org/10.1182/blood.V126.23.2752.2752
Published: 2015
Journal Articles

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Thomas S. Lin, MD, PhD, Beth Fischer, RN, Kristie A. Blum, MD, Leslie A. Andritsos, MD, Jeffrey A. Jones, MD,MPH, Mollie E. Moran, CNP, Sarah Broering, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Larry J. Schaaf, PhD, Linda S. Mahoney, RN, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 3104.
https://doi.org/10.1182/blood.V110.11.3104.3104
Published: 2007
Journal Articles

Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts).

Nyla A. Heerema, PhD, John C. Byrd, MD, Leslie A. Andritsos, MD, Gerard Lozanski, MD, Kristie Blum, MD, Beth Fischer, RN, Jeffrey A. Jones, MD, Mollie E. Moran, CNP, Sarah Groering, Larry J. Schaaf, Linda S. Mahoney, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Chelsey A. Raymond, BS, Mitch A. Phelps, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Thomas S. Lin, MD
Journal: Blood
Blood (2007) 110 (11): 3107.
https://doi.org/10.1182/blood.V110.11.3107.3107
Published: 2007
Journal Articles

Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells.

David M. Lucas, PhD, Syed-Rehan A. Hussain, PhD, Amy J. Johnson, PhD, Lisa L. Smith, MS, Amy J. Wagner, BA, Jamie M. Allison, BA, Sara E. Guster, MS/MBA, Thomas S. Lin, MD, John C. Byrd, MD, Mark W. Julian, PhD, Elliott D. Crouser, MD, Michael R. Grever, MD
Journal: Blood
Blood (2006) 108 (11): 2098.
https://doi.org/10.1182/blood.V108.11.2098.2098
Published: 2006
Journal Articles

The Geldanamycin Derivative DMAG Demonstrates Improved Cytotoxicity and Down-Modulation of Hsp90 Client Proteins Relative to 17-AAG in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Clinical Trials in CLL.

Amy J. Johnson, PhD, Amy J. Wagner, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Michael D. De Lay, BA, Jamie M. Allison, BA, S. Percy Ivy, MD, Thomas S. Lin, MD,PhD, John C. Byrd, MD
Journal: Blood
Blood (2006) 108 (11): 2101.
https://doi.org/10.1182/blood.V108.11.2101.2101
Published: 2006
Journal Articles

The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia.

Amy J. Johnson, PhD, Ryan Edwards, BA, Lisa L. Smith, MS, David M. Lucas, PhD, Carlo M. Croce, MD, Natarajan Muthusamy, DVM, PhD, Ching-Shih Chen, PhD, Zhongfa Liu, PhD, Kenneth Chan, PhD, Michael R. Grever, MD, John C. Byrd, MD
Journal: Blood
Blood (2005) 106 (11): 51.
https://doi.org/10.1182/blood.V106.11.51.51
Published: 2005